Core Viewpoint - The investment thesis for Stryker Corporation (NYSE: SYK) is based on the anticipated launch of Mako shoulder and spine applications, which has contributed to a significant stock price increase of over 28% since December 2023, outperforming the S&P 500 index [1] Company Summary - Stryker Corporation's stock has seen a notable increase of more than 28% since the presentation of the Buy thesis in December 2023 [1] - The company's performance is linked to the potential launch of new applications for its Mako robotic surgical system, specifically in shoulder and spine procedures [1] Market Performance - Stryker's stock performance has outpaced the S&P 500 index, indicating strong market confidence in the company's future growth prospects [1]

Stryker (SYK) FY 2025 Annual General Meeting May 08, 2025 09:30 AM ET Speaker0 Welcome to Stryker's Annual Meeting of Shareholders. This meeting is being recorded. Before we begin, I would like to remind you that the discussions during the meeting will include forward looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non GAAP financial measures. Reconciliations to the mo ...

Core Insights - Stryker reported revenue of $5.87 billion for the quarter ended March 2025, reflecting an 11.9% increase year-over-year and surpassing the Zacks Consensus Estimate of $5.7 billion by 2.88% [1] - The company's EPS for the quarter was $2.84, up from $2.50 in the same quarter last year, exceeding the consensus estimate of $2.73 by 4.03% [1] Financial Performance - Net sales in the United States reached $4.44 billion, exceeding the average analyst estimate of $4.25 billion, representing a year-over-year increase of 13.4% [4] - International net sales totaled $1.43 billion, slightly below the average estimate of $1.44 billion, with a year-over-year growth of 7.3% [4] - Orthopaedics net sales amounted to $2.36 billion, surpassing the average estimate of $2.31 billion, marking a 5% increase year-over-year [4] Segment Performance - MedSurg and Neurotechnology sales were reported at $3.51 billion, exceeding the average estimate of $3.41 billion, with a significant year-over-year increase of 17.1% [4] - Orthopaedics- Trauma and Extremities sales reached $945 million, above the average estimate of $902.89 million, reflecting a 13.9% year-over-year increase [4] - Orthopaedics- Spinal Implants sales were $166 million, falling short of the average estimate of $172.83 million, showing a substantial year-over-year decline of 44.7% [4] Stock Performance - Stryker's shares have returned +1.6% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Stryker Corporation (SYK) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.84, which beat the Zacks Consensus Estimate of $2.73 by 4%. The bottom line also improved 13.6% year over year. Our model estimate for the metric was pegged at $2.77 per share.GAAP EPS was $1.41, down 17.6% from the year-ago quarter’s level. The significant decline was primarily due to the impact of the Inari Medical acquisition and higher interest expenses. (Find the latest EPS estimates and surprises on Zacks Ear ...

| UNITED STATES | | --- | | SECURITIES AND EXCHANGE COMMISSION | | Washington, D.C. 20549 | | FORM 10-Q | | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | For the quarterly period ended March 31, 2025 | | OR | | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | Commission file number: 001-13149 | | STRYKER CORPORATION | | (Exact name of registrant as specified in its charter) | | Michigan 38-1239739 | | 1941 Stryker ...

Stryker (SYK) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.73 per share. This compares to earnings of $2.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.03%. A quarter ago, it was expected that this medical device maker would post earnings of $3.87 per share when it actually produced earnings of $4.01, delivering a surprise of 3.62%.Over the last four quarters, the compan ...

Financial Data and Key Metrics Changes - The company reported robust organic sales growth of 10.1% in Q1 2025, with adjusted EPS of $2.84, reflecting a 13.6% increase compared to Q1 2024 [5][6][16] - The adjusted gross margin improved to 65.5%, up 190 basis points year-over-year, while the adjusted operating margin was 22.9%, an increase of 100 basis points [23][27] - The company anticipates full-year organic sales growth of 8.5% to 9.5% and adjusted EPS in the range of $13.2 to $13.45 [7][26][27] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 10.7%, with U.S. growth at 11.4% and international growth at 8.2% [16][19] - The Instruments segment saw U.S. organic sales growth of 10.4%, while Endoscopy reported 11.1% growth driven by core portfolios [17][18] - Orthopedics had organic sales growth of 9.3%, with U.S. knee business growing 8.3% and trauma and extremities growing 15.2% [19][20][21] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.7%, while international organic sales growth was 8.5%, with notable strength in Australia, New Zealand, Japan, and Europe [15][19] - The company noted a favorable pricing impact of 0.7%, while foreign currency had a 0.9% unfavorable impact on sales [14][15] Company Strategy and Development Direction - The company completed the acquisition of Inari Medical, with integration going well and expected to contribute positively to the vascular division [7][12][50] - The company continues to focus on innovation and product launches, including the Mako robotic system and the Pangaea plating system, which are expected to drive future growth [10][11][12][58] - The company is addressing tariff impacts through pricing strategies, operational efficiencies, and leveraging its manufacturing footprint [27][33][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, citing strong demand and no significant red flags in the operating environment [35][40] - Supply chain disruptions were acknowledged, particularly in the medical segment, but these were factored into the guidance [40] - The company remains optimistic about maintaining strong sales momentum and achieving its margin improvement targets despite tariff challenges [27][44][68] Other Important Information - The company has been recognized for the fifteenth consecutive year on Great Place to Work's list of 100 Best Companies to Work For, highlighting its strong corporate culture [8] - The company expects a tariff impact of approximately $200 million in 2025, with ongoing efforts to mitigate this through various strategies [27][33] Q&A Session Summary Question: How is the company planning to absorb the estimated $200 million tariff impact? - Management indicated that the absorption will come from strong sales momentum, pricing strategies, and optimizing operational expenditures [30][32] Question: What is the outlook for the orthopedics market and the company's positioning? - Management noted that the orthopedics market remains healthy, with expectations for growth above the market average due to strong demand and successful product launches [34][35] Question: Can you provide insights on the gross margin expectations for the rest of the year? - Management expects a balanced contribution to margin improvement from both gross margin and operational expenditures, despite potential tariff impacts in the latter half of the year [42][44] Question: How is the integration of Inari progressing? - The integration is going well, with positive early performance and alignment with the company's culture [50] Question: What are the expectations for capital expenditures in 2026? - Management indicated that it is too early to provide a detailed outlook for 2026, but they remain optimistic about capital needs tied to strong procedural volumes [102]

Financial Data and Key Metrics Changes - The company reported robust organic sales growth of 10.1% in Q1 2025, with adjusted EPS of $2.84, reflecting a 13.6% increase compared to Q1 2024 [5][6][16] - The adjusted gross margin improved to 65.5%, up 190 basis points year-over-year, while the adjusted operating margin was 22.9%, an increase of 100 basis points [24][25] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 10.7%, with U.S. growth at 11.4% and international growth at 8.2% [16][20] - Orthopedics saw organic sales growth of 9.3%, with U.S. knee business growing 8.3% and hip business growing 7.6% [20][21] - Trauma and Extremities businesses grew 15.2% organically, driven by strong performance in core trauma and upper extremities [22][58] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.7%, while international organic sales growth was 8.5%, with notable strength in Australia, New Zealand, Japan, and Europe [15][20] - The company anticipates continued strength in procedural demand, particularly in robotic-assisted surgery [9][10] Company Strategy and Development Direction - The company completed the acquisition of Inari Medical, with integration going well and expected to contribute positively to the vascular division [6][12][51] - The company is focused on maintaining double-digit organic sales growth, with guidance for 2025 set at 8.5% to 9.5% [6][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, citing strong demand and no major red flags in the operating environment [41][42] - The company is taking measures to mitigate the estimated $200 million impact from tariffs through pricing strategies and operational efficiencies [27][34] Other Important Information - The company is recognized for the fifteenth consecutive year on Great Place to Work's list of 100 Best Companies to Work For [7] - The company expects to launch Mako Spine in the second half of 2025 and Mako Shoulder in Q1 2026 [10][12] Q&A Session Summary Question: How is the company absorbing the $200 million tariff impact? - The company plans to offset the tariff impact through strong sales momentum, pricing strategies, and optimizing the supply chain [31][34] Question: What is the outlook for the orthopedics market? - The orthopedics market remains healthy, with strong demand and expectations for growth above the market average [36][37] Question: How is the launch of LifePack 35 progressing? - The launch is going well, with strong order pipelines and positive market reception [68][70] Question: What are the expectations for capital expenditures in 2026? - Early conversations suggest continued strength in capital demand, particularly tied to procedural needs [100][101] Question: How is the integration of Inari going? - The integration is progressing well, with strong early performance and alignment with Stryker's culture [51][52]

Exhibit 99.1 STRYKER REPORTS FIRST QUARTER 2025 OPERATING RESULTS Portage, Michigan - May 1, 2025 - Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results | | | First Quarter Net Sales Growth Overview | | | | --- | --- | --- | --- | --- | | | Foreign Currency | | Acquisitions / | | | | Reported Exchange | Constant Currency | Divestitures | Organic | | MedSurg and Neurotechnology | 13.4 % (0.8)% | 14.2 % | 3.5 % | 10.7 % | | Orthopaedics | 9.7 (1.0) | 10.7 | 1.4 | ...

Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acq ...